Search research articles
Contact Us
Filters
Showing results (41-50 of 59) with videos related to
Page
of 6
Sort By:
The Lancet. HIV
|
December 7, 2023
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study
Deborah Persaud, Yvonne Bryson, Bryan S Nelson, et al.
Journal of the Pediatric Infectious Diseases Society
|
January 17, 2025
Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07-523LS in Newborn Infants Exposed to HIV-1
Coleen K Cunningham, Elizabeth J McFarland, Petronella Muresan, et al.
Antimicrobial Agents and Chemotherapy
|
May 25, 2021
Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Antonio C Arrieta, Michael Neely, J Christopher Day, et al.
The Lancet. HIV
|
March 27, 2024
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study
Elizabeth D Lowenthal, Jennifer Chapman, Rachel Ohrenschall, et al.
The Pediatric Infectious Disease Journal
|
May 29, 2025
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results
Helena Rabie, Dwight E Yin, Shawn Ward, et al.
Depression and Anxiety
|
April 5, 2013
Depressive disorders among children in the transforming China: an epidemiological survey of prevalence, correlates, and service use
Bao-liang Zhong, Jun Ding, Hong-hui Chen, et al.
Transplantation and Cellular Therapy
|
July 7, 2022
Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study
Neel S Bhatt, Akshay Sharma, Andrew St Martin, et al.
The Lancet. HIV
|
January 17, 2026
Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial
Elizabeth D Lowenthal, Jennifer Chapman, Kristin Baltrusaitis, et al.
The Lancet. HIV
|
January 17, 2026
Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study
Aditya H Gaur, Kristin Baltrusaitis, Edmund V Capparelli, et al.
The Journal of Infectious Diseases
|
June 5, 2024
Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032
Kristina M Brooks, Kristin Baltrusaitis, Diana F Clarke, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 59) with videos related to
Sort By:
Page
of 6
The Lancet. HIV
|
December 7, 2023
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study
Deborah Persaud, Yvonne Bryson, Bryan S Nelson, et al.
Journal of the Pediatric Infectious Diseases Society
|
January 17, 2025
Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07-523LS in Newborn Infants Exposed to HIV-1
Coleen K Cunningham, Elizabeth J McFarland, Petronella Muresan, et al.
Antimicrobial Agents and Chemotherapy
|
May 25, 2021
Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Antonio C Arrieta, Michael Neely, J Christopher Day, et al.
The Lancet. HIV
|
March 27, 2024
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study
Elizabeth D Lowenthal, Jennifer Chapman, Rachel Ohrenschall, et al.
The Pediatric Infectious Disease Journal
|
May 29, 2025
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results
Helena Rabie, Dwight E Yin, Shawn Ward, et al.
Depression and Anxiety
|
April 5, 2013
Depressive disorders among children in the transforming China: an epidemiological survey of prevalence, correlates, and service use
Bao-liang Zhong, Jun Ding, Hong-hui Chen, et al.
Transplantation and Cellular Therapy
|
July 7, 2022
Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Hematopoietic Stem Cell Transplant Recipients: A Cohort Study
Neel S Bhatt, Akshay Sharma, Andrew St Martin, et al.
The Lancet. HIV
|
January 17, 2026
Acceptability and tolerability of long-acting injectable cabotegravir-rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial
Elizabeth D Lowenthal, Jennifer Chapman, Kristin Baltrusaitis, et al.
The Lancet. HIV
|
January 17, 2026
Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir-rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study
Aditya H Gaur, Kristin Baltrusaitis, Edmund V Capparelli, et al.
The Journal of Infectious Diseases
|
June 5, 2024
Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032
Kristina M Brooks, Kristin Baltrusaitis, Diana F Clarke, et al.
Page
of 6